Ovarian Cancer | Specialty

Addition of Dostarlimab to Chemo and Niraparib Maintenance Boosts PFS in Advanced Ovarian Cancer

December 20th 2024

Adding dostarlimab to chemotherapy and niraparib maintenance improved progression-free survival in first-line advanced ovarian cancer.

Lunresertib Plus Camonsertib Produces Durable Responses in Advanced Endometrial, Ovarian Cancer

December 19th 2024

Lunresertib plus camonsertib demonstrated efficacy and safety in heavily pretreated endometrial cancer and platinum-resistant ovarian cancer.

IMNN-001 Plus Perioperative Chemotherapy Maintains OS Benefit in Newly Diagnosed Advanced Ovarian Cancer

December 10th 2024

After an additional 7 months of follow-up, IMNN-001 plus chemotherapy produced a 13-month increase in median OS in advanced ovarian cancer

Luveltamab Tazevibulin Produces Responses in Platinum-Resistant Ovarian Cancer

December 10th 2024

Luveltamab tazevibulin produced responses in patients with platinum-resistant ovarian cancer.

Pembrolizumab/Chemo, Followed by Olaparib Maintenance, Boosts PFS in Advanced Ovarian Cancer

December 9th 2024

Pembrolizumab plus chemotherapy, followed by olaparib with or without bevacizumab, improved PFS in advanced ovarian cancer.

IMNN-001 Plus Chemo Data Highlight Potential to Fill Unmet Need in Ovarian Cancer

December 2nd 2024

Premal Thaker, MD, MS, highlights data seen with the IL-12 Immunotherapy IMNN-001 in the OVATION-2 trial and next steps with the agent in ovarian cancer.

Revisit Every OncLive On Air Episode From November 2024

December 2nd 2024

In case you missed any, read a recap of every episode of OncLive On Air that aired in November 2024.

Targeting IL-12 Safely With Intraperitoneal Therapy Represents Key Step Forward in Ovarian Cancer

November 28th 2024

Premal Thaker, MD, MS, discusses considerations when targeting IL-12 in ovarian cancer and how IMNN-001 has shown the potential to do so.

Dr Moore on Key 2024 Updates in FRα+ Ovarian Cancer Management

November 27th 2024

Dr Moore on Ongoing ADC Development in Ovarian Cancer

November 27th 2024

Kathleen N. Moore, MD, MS, discusses novel antibody-drug conjugates under investigation in ovarian cancer.

Olaparib Leads PARP Inhibitor Charge in the Treatment of BRCA-Mutated, HRD Ovarian Cancer

November 21st 2024

Whitney Goldsberry, MD, discusses patient characteristics and disease factors that sway the decision between available PARP inhibitors in ovarian cancer.

European Commission Approves Mirvetuximab Soravtansine for FRα+ Platinum-Resistant Ovarian Cancer

November 18th 2024

The European Commission has approved mirvetuximab soravtansine for select patients with pretreated FRα-positive, platinum-resistant ovarian cancer.

The OncFive: Top Oncology Articles for the Week of 11/10

November 16th 2024

New datopotamab deruxtecan BLA in NSCLC filed to FDA, radiopharmaceutical meets rPFS end point in PSMA+ prostate cancer, and more.

Dr Scalici on Data for IMNN-001 Plus SOC Chemotherapy in Advanced Ovarian Cancer

November 15th 2024

Jennifer Scalici, MD, discusses data for IMNN-001plus chemotherapy in advanced ovarian cancer.

Sacituzumab Tirumotecan Shows Antitumor Activity in Previously Treated Endometrial, Ovarian Cancers

November 14th 2024

Sacituzumab tirumotecan monotherapy demonstrated antitumor activity with a manageable safety profile in previously treated endometrial and ovarian cancers.

NXP800 Demonstrates Single-Agent Activity in ARID1a+ Platinum-Resistant Ovarian Cancer

November 14th 2024

NXP800 generated antitumor activity as monotherapy in platinum-resistant ovarian cancer harboring ARID1a mutations.

Refined Definition of Platinum Resistance, Novel ADCs Could Bring More Changes to Ovarian Cancer Treatment

November 12th 2024

Kathleen N. Moore, MD, MS, discusses the evolving treatment landscape of platinum-resistant ovarian cancer.

Dr Thaker on the Role of the Glucocorticoid Pathway in Platinum-Resistant Ovarian Cancer

November 8th 2024

Premal Thaker, MD, MS, discusses the role of the glucocorticoid receptor pathway and the development of chemoresistance in ovarian cancer.

BT7480 Shows Preliminary Activity in Nectin-4+, CD137+ Tumors

November 7th 2024

The Nectin-4/CD137 Bicycle–targeted immune cell agonist BT7480 had antitumor activity in patients with Nectin-4– and CD137-expressing tumors.

Dr Moore on the Evolving Treatment Landscape for Platinum-Resistant Ovarian Cancer

November 4th 2024

Kathleen N. Moore, MD, MS, discusses the evolving landscape in managing platinum-resistant ovarian cancer.